Drug Profile

Vesemnogene lantuparvovec - Lantu Biopharma

Alternative Names: AAV-hSMN1

Latest Information Update: 29 Jul 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Lantu Biopharma
Class Gene therapies; Spinal muscular atrophy gene therapies
Mechanism of Action Gene transference; Survival of motor neuron 1 protein replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

19 Jul 2024 Phase-I/II clinical trials in Spinal muscular atrophy (In children, In adults) in China (IV) (NCT06288230)
01 Mar 2024 Preclinical trials in Spinal muscular atrophy in China (Parenteral)
01 Mar 2024 Lantu Biopharma plans a phase I/II trial for Spinal muscular atrophy (IV) in March 2024 (NCT06288230)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com